We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Preattached Holder Protects Phlebotomists Against Needlestick Injury

By LabMedica International staff writers
Posted on 08 Jun 2010
A push button blood collection set with a preattached holder is now available to protect health care workers from accidental needlestick injuries (NSIs). More...
The ready-to-use product will also prevent reuse of the tube holder.

Needlestick and sharps injuries carry the risk of infections and are an occupational hazard for all healthcare professionals involved in clinical care. The preassembled device saves time by shortening the blood collection process; the preattached holder covers the holder end of the needle, reducing the risk of injury.

The intuitively designed apparatus consists of a large flexible wing flanking the needle, a push button safety mechanism, and tubing that does not kink or coil. This is connected to the single use holder by way of a luer adaptor. The blood collection set is manufactured by Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) and is an improved version of the original Vacutainer collection sets. The new product's in-vein activation of the safety device provides split-second protection against NSIs.

Tube holders that are reused have not been disinfected or sterilized, posing unnecessary exposure to blood borne pathogens including human immunodeficiency virus (HIV), hepatitis C virus, and hepatitis B virus. The National Phlebotomy Association (NPA; Landover, MD, USA) recently completed a study on reusable blood tube holders. The study revealed that 99% of holders sampled, were contaminated with blood. This poses an occupational exposure risk to the healthcare worker and an infection-control exposure risk to the patient.

Single-use holders that are preattached to safety-engineered blood collection needles may provide the highest level of infection prevention for the healthcare industry. One hospital reported an 88% reduction in NSIs after adopting the device, with zero NSIs in the final 21 months after implementing the product.

Dr. Ana Stankovic, M.D, Ph.D., M.S.P.H., world VP at BD diagnostics said, "this product virtually eliminates a healthcare worker's exposure to a contaminated needle and reduces the time required to collect blood for diagnostic testing."

Related Links:

Becton, Dickinson and Company
National Phlebotomy Association



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.